Pharmaceutical compositions and methods to vaccinate against candidiasis
US8541008B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Sep 13, 2002 |
| Grant date | Sep 24, 2013 |
| Priority date | — |
| Expiry date | Aug 16, 2025 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2039/53
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A Candida albicans bloodstream infections cause significant morbidity and mortality in hospitalized patients. Filament formation and adherence to host cells are critical virulence factors of C. albicans. Multiple filamentation regulatory pathways have been discovered, however the downstream effectors of these regulatory pathways remain unknown. The cell surface proteins in the ALS group are downstream effectors of the filamentation regulatory pathway. Particularly, Als1p mediates adherence to endothelial cells in vitro and is required for virulence. The blocking of adherence by the organism is described resulting from the use of a composition and method disclosed herein. Specifically, a pharmaceutical composition comprised of a gene, gene product, or specific antibody to the ALS gene family is administered as a vaccine to generate an immune response capable of blocking adherence of the organism.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.